# Christoph Lengauer

> Christoph Lengauer is a startup investor at Curie.Bio (Boston). See 0 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Curie.Bio](https://shizune.co/investors/profile/curie-bio)
- Location: Boston, United States
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/christoph-lengauer-75b7961b

Christoph Lengauer is a startup investor at Curie.Bio in Boston. Christoph is Co-Founder and CSO at Curie.Bio. Curie.Bio is a founder-focused seed-stage venture firm combined with an industry-grade therapeutics accelerator focused on one thing: helping entrepreneurial founders launch viable therapeutics companies. Curie.Bio does this by giving founders access to a team of the world’s best drug hunters and drugmakers, seed capital, and best-of-breed services - everything a founder needs to get from concept to a compelling dataset that enables an awesome Series A financing. And we do this at scale for 40+ companies / year.Christoph was previously a Venture Partner at Third Rock Ventures, where he helped discover, launch, and build companies based on bold ideas that meet at the intersection of science, strategy, business, and medicine. He was also previously President of Celsius Therapeutics, a startup that develops medicines by understanding the ecosystem of cells using single-cell genomics.In fall of 2015, Christoph was appointed CEO by the German Ministry for Economy to lead the buildout of the German Accelerator Life Sciences (GALS) in Cambridge, MA and Berlin, Germany. GALS provides high-end consulting to emerging German life-science companies and supports them with introducing their products to the US market. In 2017, Christoph founded Advise.Connect.Inspire, which provides similar services to companies across all of Europe.Christoph was also formerly Executive Vice President at Blueprint Medicines (BPMC), where he was the founding CSO and has been leading the clinical progression of BLU-285 until its recent breakthrough therapy designation granted by the FDA for the treatment of patients with unresectable or metastatic PDGFRA D842V mutated gastrointestinal stromal tumors.Christoph has a proven record in drug discovery and contributed to more than 25 drugs that reached human clinical trials as well as four approved lifesaving medicines (Kisqali, Odomzo, Zaltrap, Jevtana). Christoph also worked for approximately ten years at Novartis and as Global Head of Oncology Drug Discovery and Preclinical Development at Sanofi.Prior to joining the pharma/biotech industry, Christoph was an associate professor at the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine in Baltimore, MD. Christoph discovered that all cancers are genetically unstable. While co-leading the Vogelstein lab for about a decade, he was involved in the identification of several cancer-driver genes, including BRAF and PIK3CA.Christoph holds adjunct associate professor positions at Johns Hopkins University and Harvard University. A strong and outspoken advocate of patients’ rights, he is featured in the New York Times bestseller and HBO movie, The Immortal Life of Henrietta Lacks.

## About Curie.Bio

VC Fund

Curie.Bio is a founder-focused seed-stage venture capital firm.

4 contacts available at Curie.Bio.

| Name | Title | Profile |
| --- | --- | --- |
| Alexis Borisy | Co-Founder & Chairman | https://shizune.co/investors/profile/alexis-borisy |
| Zach Weinberg | Co-Founder and CEO | https://shizune.co/investors/profile/zach-weinberg |
| Ben Auspitz | Managing Partner, Breakout Fund | https://shizune.co/investors/profile/ben-auspitz |
| Christoph Lengauer | Co-Founder and CSO | https://shizune.co/investors/profile/christoph-lengauer |

## FAQ

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co